An observational study in Frailty, Intrinsic Capacity and Lifestyle, sponsored by National University Hospital, Singapore. Recruiting at 1 site in Singapore. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by National University Hospital, Singapore · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Frailty with a site in Singapore — 12 open to participants now, 13 under way, none of them phase 3. Frailty · Singapore.
Among the 28 studies in Frailty with a site in Singapore, this one is one of 5 that started in 2025, is one of 7 observational ones, reaches primary completion later than 9 of the 12 other live ones, and was the 27th registered.
1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.
Browse Frailty studies →12 of the 28 studies in Frailty with a site in Singapore are open now. Recruiting first, the newest first:
Changi General Hospital · Sites in Singapore
Ages 65+ · Healthy volunteers
National University of Singapore · Sites in Singapore
Ages 50–80
National University of Singapore · Sites in Singapore
Ages 60–85 · Healthy volunteers
National University of Singapore · Sites in Singapore
Ages 60–85 · Healthy volunteers
Tan Tock Seng Hospital · Sites in Singapore
Ages 50+
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 5 started in 2025.
This study's planned enrollment of 2,500 is above the median of 225 across 495 observational studies indexed under Frailty.
Median enrollment 140 across the 21 interventional studies, 345 across the 7 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 28 have an industry lead sponsor. The 10 most frequent:
National University Hospital, Singapore is the lead sponsor of 455 studies on the registry; 100 are open to participants now.
National University Hospital, Singapore has 3 studies filed under Frailty — fewer than ten, so there is no comparison to draw.
6 of the studies in Frailty with a site in Singapore that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07081191National University of SingaporeDose-response Effect of Community Dance Programme | 2026-12 |
| NCT06073106Tan Tock Seng HospitalTargeting Osteosarcopaenia and Multimorbidity for Frailty Prevention | 2027-01 |
| NCT07081282National University of SingaporePrecision Stratification for Frailty and Cognitive Decline | 2027-01-31 |
| NCT07205133Changi General HospitalA Randomized Controlled Trial Comparing Whole Body Vibration Therapy With Usual Care and Usual Care to Improve Muscle Health in Older Adults | 2027-03-31 |
| NCT07525583National University Hospital, SingaporeImplementation of Decade of Healthy Ageing Action Plan to Screen and Prevent Decline in Intrinsic Capacity in Elders (SPICE) Through Multisectoral Collaboration in Singapore | 2027-05-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 28 studies in Frailty with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the implementation of a structured community-based pathway to screen, risk stratify, and prevent decline in intrinsic capacity (IC) among adults aged 60 years and above in Singapore. Using the World Health Organization (WHO) Integrated Care for Older People (ICOPE) framework and digital screening tools, participants will undergo IC domain screening in community settings. Individuals identified with early decline will receive targeted multidomain interventions and/or referral to primary or specialist care as indicated. Participants will be followed longitudinally to assess feasibility, uptake, functional trajectories, and implementation outcomes.
Population ageing is associated with progressive decline in intrinsic capacity (IC), defined by WHO as the composite of physical and mental capacities across mobility, cognition, vitality (nutrition), psychological, and sensory domains. Early detection of IC decline enables preventive, person-centred interventions to delay frailty, disability, and long-term care dependency.
The SPICE study operationalises the WHO ICOPE framework within Singapore's community ageing ecosystem through a coordinated hub-and-spoke model linking:Community screening platforms (e.g., Active Ageing Centres), Community Health Posts, Regional health system services and other social service organisations.
The pathway consists of:
Step 1: IC Screening
Step 3: Risk Stratification \& Care Planning
Step 4: Intervention \& Referral
Step 5: Monitoring \& Follow-up
In addition, blood and digital biomarkers will be collected from a subgroup of study participants.
Recruitment will be conducted from Active Ageing Centre and Community Centres.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Community-dwelling adults robust or pre-frail aged 60 years and above who undergo WHO ICOPE-aligned digital intrinsic capacity screening, structured risk stratification, personalised multidomain community-based interventions, and longitudinal follow-up.
Other: ICOPE-Based Digital Intrinsic Capacity Monitoring and Triggered Follow-up (SPICE Pathway)
Participants will undergo baseline intrinsic capacity (IC) screening using WHO ICOPE-aligned tools in community settings. Follow-up contacts/visits will occur over the study period and include: 1. Scheduled follow-up at predefined intervals (e.g., every 3, 6-12 months) for repeat IC assessment and outcome data collection; and 2. Triggered (non-scheduled) follow-up that is initiated when remote/digital monitoring indicates decline in one or more IC domains, poor adherence, or when major intercurrent clinical events are reported/identified, prompting in-depth assessment, care plan adjustment, and referral to Community Health Posts, primary care, or specialist services as appropriate.
Prevalence of intrinsic capacity decline at baseline (robust / pre-frail)
Proportion of participants (restricted to robust and pre-frail at baseline) with ≥1 impaired IC domain on screening; and proportion impaired by each domain (mobility, cognition, vitality, psychological, sensory).
Time frame: Baseline
Uptake of recommended actions (implementation effectiveness)
Proportion of participants who initiate at least one recommended action within a defined window after screening/plan (e.g., enrolment in a prescribed community programme, completion of recommended assessment, or attendance at a referred service).
Time frame: Up to 3 months post-recommendation
Identification of (a set of) biomarkers of aging
Both blood biomarkers and digital markers associated with various intrinsic capacity
Time frame: 30 months
Feasibility and reach
Proportion of individuals in each community setting complete both Step 1 and Step 2 assessment.
Time frame: 30 months
Change in intrinsic capacity and function over time
Change in number of impaired IC domains (0-5) from baseline to follow-up.
Time frame: 12 months from enrolment
Frailty progression
Proportion transitioning from robust → pre-frail/frail; pre-frail → frail
Time frame: over 12 months follow up
Cost per participant screened
Programme delivery cost from the provider/programme perspective, calculated as total programme delivery cost divided by the number of participants screened; costs include personnel, training, digital platform/monitoring, screening and assessment delivery, and intervention coordination.
Time frame: 3 years
Number of participants with at least one unscheduled emergency department visit or hospital admission
Number and proportion of participants with at least one unscheduled emergency department visit or unplanned hospital admission during follow-up, based on participant report and/or clinical records where available.
Time frame: 12 months
Implementation outcomes assessed using RE-AIM framework
Reach: Proportion of eligible older adults screened, characteristics of participants. Effectiveness: Proportion of participants with identified IC impairment who receive recommended follow-up actions, including referral to community services, primary care, or multidisciplinary assessment. Adoption: Provider-reported acceptability and perceived usefulness of the screening pathway (measured using an adapted 8-item questionnaire based on the Theoretical Framework of Acceptability (TFA)). Implementation: Adherence to screening protocols among providers, completion of Step 1 and Step 2 assessments, and referral processes. Implementation strategies, barriers, and facilitators will also be documented by qualitative method. Maintenance: Continued delivery of IC screening at participating sites, and Integration of the programme into routine community health services. The 23-item Normalization Measure Development questionnaire (NoMAD) and the 12-item SCIROCCO tool will be used.
Time frame: 3 years
Plan to share: Undecided — It will not be individual level data but rather a group data.
Started Apr 2025 (actual). Primary completion is estimated for May 2027, 25 months after the start.
Of 291 non-industry observational studies under Frailty, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 25 months is below that.
Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 12 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National University Hospital, Singapore →